Hepatitis/MASH

Eating animal protein may increase the risk of non-alcoholic fatty liver disease development.

Patients who received kidney transplants from donors infected with hepatitis C virus were cured after antiviral drug therapy.

Direct-acting antiviral agents have the potential to substantially increase the number of kidney transplants by making infected kidneys available.

Opioid epidemic fuels hepatitis C transmission.

Ledipasvir/sofosbuvir combination resulted in beneficial viral response in pediatric patients.

Estimates of patients with HCV dropped from 130 million to 71 million.

Statins also found to lower rates of decompensation in patients with liver cirrhosis related to nonalcoholic steatohepatitis.

Statins could be used as adjuvant therapy to prevent decompensation, study suggests.

Glecaprevir/pibrentasvir combination shows promise as a novel hepatitis C virus treatment.

Efforts to reduce injection frequency can have positive health benefits with or without HIV infection, study suggests.

The vending machines dispense kits containing sterile syringes and needles in hopes of reducing the spread of infectious disease.

Top articles of the week from The American Journal of Pharmacy Benefits.

Real world observational study supports data on sustained hepatitis C virologic response rates.

Real world data from treatment with elbasvir/grazoprevir supports response rates found in trials of chronic hepatitis C drug.

Glecaprevir/pibrentasvir achieved 99% sustained virologic response rate in patients with chronic HCV with compensated cirrhosis.

Experimental glecaprevir/pibrentasvir treatment shows efficacy across hepatitis C genotypes.

The final part of a 4-part interview with an infectious disease expert examines the furture treatment landscape and caring for an aging HIV population.

Top news of the day from across the health care landscape.

Top news of the day from across the healthcare landscape.

The third of a 4-part interview with an infectious disease expert discusses the impact of specialty drugs and the potential loss of funding to HIV treatment programs.

A recently-published study evaluated the relationship between injection drug use and immune activation in people who inject drugs (PWID) and who have or do not have HIV.

The second of 4-part interview with an infectious disease expert examines weighing the short-term high cost of treating HCV with curative drugs versus the long-term costs of treating the disease.

Individuals susceptible to hepatitis infection may also be susceptible to Parkinson’s disease.

Individuals with hepatitis B and hepatitis C may be more susceptible to Parkinson’s disease.

Part 1 of a 4-part interview with an infectious disease expert explores treatment advances in HIV since the AIDS epidemic in the 1980s.